miR-155在弥漫性大B细胞淋巴瘤发病中的作用及可能机制

Role of miR-155 in Pathogenesis of Diffuse Large B Cell Lymphoma and Its Possible Mechanism——Review

弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)是最常见的侵袭性非霍奇金淋巴瘤(nonHodgkin's lymphoma,NHL),占成人NHL的30%-40%,5年生存率在25%左右。虽然现今已经有DLBCL的标准治疗方案,但是仍约有50%的患者不能治愈,因此了解调控DLBCL的发病机制,探索新的有效的治疗方法仍是研究者努力的方向。microRNA是近年来生物学研究的一大焦点,它是由一段非常短的非编码RNA序列组成,对多种生物学过程起调控作用。研究发现,miR-155是最著名的致瘤microRNA之一,在很多淋巴瘤中都过表达,在DLBCL中更是异常高表达。miR-155可以通过BMP/TGF-β和RhoA等多种信号通路促进淋巴瘤的发生,有望成为治疗DLBCL的新靶点。本文就miR-155在弥漫性大B细胞淋巴瘤发病中的作用和可能机制做一综述。

Diffuse large B cell lymphoma（DLBCL） is the most common subtype of invasive non-Hodgkin＇s lymphoma（ NHL）, account for 30% -40% of NHL in adults, the 5-year survival rate is approximately 25%. Although there was a standard treatment to DLBCL today, approximately 50% of patients can not be cured. As a result, it is still a diligent direction of the researchers to understand the pathogenesis of DLBCL and to explore new effective treatment. Re- cently, the study of microRNA is a hot topic in biology, microRNAs are a class of small non-coding RNA that have emerged to regulate various of biological processes. MiR-155 is one of the most well-known oncogenic micro-RNA, miR- 155 overexpression has been documented in a number of lymphoid neoplasms, extraordinarily in DLBCL. MiR-155 can promote the occurrence of lymphoma through various signaling pathways, such as the BMP/TGF-β and RhoA pathway, it is expected to become a new target for treatment of DLBCL. This article reviews the role and possible mechanisms of miR-155 in the laathogenesis of DLBCL.